These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 24374141)
21. Characterization and regulation of wild-type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension. Cunningham KP; Holden RG; Escribano-Subias PM; Cogolludo A; Veale EL; Mathie A J Physiol; 2019 Feb; 597(4):1087-1101. PubMed ID: 30365877 [TBL] [Abstract][Full Text] [Related]
22. Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo. Jacobson I; Duker G; Florentzson M; Linhardt G; Lindhardt E; Nordkam AK; Åstrand A; Carlsson L J Cardiovasc Pharmacol Ther; 2013 May; 18(3):290-300. PubMed ID: 23307834 [TBL] [Abstract][Full Text] [Related]
23. Functional role of TASK-1 in the heart: studies in TASK-1-deficient mice show prolonged cardiac repolarization and reduced heart rate variability. Donner BC; Schullenberg M; Geduldig N; Hüning A; Mersmann J; Zacharowski K; Kovacevic A; Decking U; Aller MI; Schmidt KG Basic Res Cardiol; 2011 Jan; 106(1):75-87. PubMed ID: 20978771 [TBL] [Abstract][Full Text] [Related]
24. Epistatic effects of potassium channel variation on cardiac repolarization and atrial fibrillation risk. Mann SA; Otway R; Guo G; Soka M; Karlsdotter L; Trivedi G; Ohanian M; Zodgekar P; Smith RA; Wouters MA; Subbiah R; Walker B; Kuchar D; Sanders P; Griffiths L; Vandenberg JI; Fatkin D J Am Coll Cardiol; 2012 Mar; 59(11):1017-25. PubMed ID: 22402074 [TBL] [Abstract][Full Text] [Related]
25. Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels. Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D Eur J Pharmacol; 2013 Dec; 721(1-3):237-48. PubMed ID: 24070813 [TBL] [Abstract][Full Text] [Related]
26. Functional Characterization of Rare Variants Implicated in Susceptibility to Lone Atrial Fibrillation. Hayashi K; Konno T; Tada H; Tani S; Liu L; Fujino N; Nohara A; Hodatsu A; Tsuda T; Tanaka Y; Kawashiri MA; Ino H; Makita N; Yamagishi M Circ Arrhythm Electrophysiol; 2015 Oct; 8(5):1095-104. PubMed ID: 26129877 [TBL] [Abstract][Full Text] [Related]
27. Upregulation of K(2P)3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation. Schmidt C; Wiedmann F; Voigt N; Zhou XB; Heijman J; Lang S; Albert V; Kallenberger S; Ruhparwar A; Szabó G; Kallenbach K; Karck M; Borggrefe M; Biliczki P; Ehrlich JR; Baczkó I; Lugenbiel P; Schweizer PA; Donner BC; Katus HA; Dobrev D; Thomas D Circulation; 2015 Jul; 132(2):82-92. PubMed ID: 25951834 [TBL] [Abstract][Full Text] [Related]
28. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. Wiedmann F; Beyersdorf C; Zhou XB; Kraft M; Paasche A; Jávorszky N; Rinné S; Sutanto H; Büscher A; Foerster KI; Blank A; El-Battrawy I; Li X; Lang S; Tochtermann U; Kremer J; Arif R; Karck M; Decher N; van Loon G; Akin I; Borggrefe M; Kallenberger S; Heijman J; Haefeli WE; Katus HA; Schmidt C Cardiovasc Res; 2022 Jun; 118(7):1728-1741. PubMed ID: 34028533 [TBL] [Abstract][Full Text] [Related]
29. Cardiac K Staudacher I; Seehausen S; Illg C; Lugenbiel P; Schweizer PA; Katus HA; Thomas D Prog Biophys Mol Biol; 2019 Jul; 144():128-138. PubMed ID: 31182191 [TBL] [Abstract][Full Text] [Related]
30. Expression of the kcnk3 potassium channel gene lessens the injury from cerebral ischemia, most likely by a general influence on blood pressure. Muhammad S; Aller MI; Maser-Gluth C; Schwaninger M; Wisden W Neuroscience; 2010 May; 167(3):758-64. PubMed ID: 20167264 [TBL] [Abstract][Full Text] [Related]
31. New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K Schmidt C; Wiedmann F; Gaubatz AR; Ratte A; Katus HA; Thomas D J Pharmacol Exp Ther; 2018 Jun; 365(3):614-623. PubMed ID: 29643254 [TBL] [Abstract][Full Text] [Related]
32. The S140G KCNQ1 atrial fibrillation mutation affects 'I(KS)' profile during both atrial and ventricular action potentials. El Harchi A; Zhang H; Hancox JC J Physiol Pharmacol; 2010 Dec; 61(6):759-64. PubMed ID: 21224508 [TBL] [Abstract][Full Text] [Related]
35. Age-related changes in two-pore domain acid-sensitive K⁺ channel expression in rat dorsal root ganglion neurons. Kim GT; Cho YW; Tak HM; Lee JS; Kim EJ; Han J; Kang D Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):43-8. PubMed ID: 22017174 [TBL] [Abstract][Full Text] [Related]
36. Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels. Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D Naunyn Schmiedebergs Arch Pharmacol; 2012 Oct; 385(10):1003-16. PubMed ID: 22790794 [TBL] [Abstract][Full Text] [Related]
37. TREK-1 (K Lugenbiel P; Wenz F; Syren P; Geschwill P; Govorov K; Seyler C; Frank D; Schweizer PA; Franke J; Weis T; Bruehl C; Schmack B; Ruhparwar A; Karck M; Frey N; Katus HA; Thomas D Basic Res Cardiol; 2017 Jan; 112(1):8. PubMed ID: 28005193 [TBL] [Abstract][Full Text] [Related]
38. Identification of native rat cerebellar granule cell currents due to background K channel KCNK5 (TASK-2). Cotten JF; Zou HL; Liu C; Au JD; Yost CS Brain Res Mol Brain Res; 2004 Sep; 128(2):112-20. PubMed ID: 15363886 [TBL] [Abstract][Full Text] [Related]
39. Amide local anesthetics potently inhibit the human tandem pore domain background K+ channel TASK-2 (KCNK5). Kindler CH; Paul M; Zou H; Liu C; Winegar BD; Gray AT; Yost CS J Pharmacol Exp Ther; 2003 Jul; 306(1):84-92. PubMed ID: 12660311 [TBL] [Abstract][Full Text] [Related]
40. Next-generation sequencing of nine atrial fibrillation candidate genes identified novel de novo mutations in patients with extreme trait of atrial fibrillation. Tsai CT; Hsieh CS; Chang SN; Chuang EY; Juang JM; Lin LY; Lai LP; Hwang JJ; Chiang FT; Lin JL J Med Genet; 2015 Jan; 52(1):28-36. PubMed ID: 25391453 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]